China To Survey Cost And Market Pricing Of Medical Insurance Drugs
This article was originally published in PharmAsia News
In tandem with China's health care reform and national basic medicine system implementation, National Development and Reform Commission recently announced that it will conduct a survey on market prices and production costs of all 1,031 Western medicines and 823 TCMs in the catalogs of national basic medical insurance and work injury insurance. The study includes product costs, market price, tender price, provincial pricing and recorded price. NDRC said that clarification about medicine cost and pricing will help the government adjust its pricing policy in a timely manner. According to Beijing Municipal Commission of Development and Reform, the city has identified Beijing Pharmaceutical, Beijing Yibao Quanxin Pharmacy, Peking University Third Hospital, Beijing No.6 Hospital and Beijing Jinsong Hospital as subjects for the survey. (Click here for more - Chinese Language)
You may also be interested in...
Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.